Pharmena S.A. (PHR.WA)
PLN 4.0
(-3.15%)
PLN 4.0
(-3.15%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -22.05 Million PLN | -1938.45% |
| 2022 | -1.08 Million PLN | -59.59% |
| 2021 | -678 Thousand PLN | 49.14% |
| 2020 | -1.33 Million PLN | -138.46% |
| 2019 | -559 Thousand PLN | -193.63% |
| 2018 | 597 Thousand PLN | -82.5% |
| 2017 | 3.41 Million PLN | -5.17% |
| 2016 | 3.59 Million PLN | 175.0% |
| 2015 | 1.3 Million PLN | 131.14% |
| 2014 | -4.2 Million PLN | 62.28% |
| 2013 | -11.13 Million PLN | -248.36% |
| 2012 | -3.19 Million PLN | 0.0% |
| 2011 | - PLN | 0.0% |
| 2010 | - PLN | 100.0% |
| 2009 | -8.76 Million PLN | 25.19% |
| 2008 | -11.71 Million PLN | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -20.6 Million PLN | 6.58% |
| 2024 Q2 | -10.76 Million PLN | 47.73% |
| 2023 Q2 | -39.92 Million PLN | -3691.93% |
| 2023 Q1 | -1.05 Million PLN | 2.68% |
| 2023 Q4 | -22.05 Million PLN | -0.54% |
| 2023 Q3 | -21.93 Million PLN | 45.06% |
| 2023 FY | -22.05 Million PLN | -1938.45% |
| 2022 Q3 | 1.54 Million PLN | 292.77% |
| 2022 Q1 | 7.64 Million PLN | 1227.43% |
| 2022 FY | -1.08 Million PLN | -59.59% |
| 2022 Q4 | -1.08 Million PLN | -169.99% |
| 2022 Q2 | -802 Thousand PLN | -110.49% |
| 2021 Q2 | -1.75 Million PLN | 30.6% |
| 2021 Q4 | -678 Thousand PLN | -31.91% |
| 2021 FY | -678 Thousand PLN | 49.14% |
| 2021 Q1 | -2.53 Million PLN | -90.02% |
| 2021 Q3 | -514 Thousand PLN | 70.76% |
| 2020 Q3 | 3.59 Million PLN | 1834.3% |
| 2020 Q4 | -1.33 Million PLN | -137.13% |
| 2020 Q2 | -207 Thousand PLN | 79.38% |
| 2020 Q1 | -1 Million PLN | -79.61% |
| 2020 FY | -1.33 Million PLN | -138.46% |
| 2019 Q3 | -1.38 Million PLN | 61.58% |
| 2019 Q1 | -4.2 Million PLN | -805.03% |
| 2019 Q4 | -559 Thousand PLN | 59.64% |
| 2019 FY | -559 Thousand PLN | -193.63% |
| 2019 Q2 | -3.6 Million PLN | 14.35% |
| 2018 Q2 | 2.86 Million PLN | -7.47% |
| 2018 FY | 597 Thousand PLN | -82.5% |
| 2018 Q4 | 597 Thousand PLN | -67.27% |
| 2018 Q3 | 1.82 Million PLN | -36.25% |
| 2018 Q1 | 3.09 Million PLN | -9.35% |
| 2017 Q4 | 3.41 Million PLN | -12.13% |
| 2017 Q3 | 3.88 Million PLN | 1.65% |
| 2017 Q1 | 2.99 Million PLN | -16.82% |
| 2017 FY | 3.41 Million PLN | -5.17% |
| 2017 Q2 | 3.81 Million PLN | 27.64% |
| 2016 Q1 | 97 Thousand PLN | -92.58% |
| 2016 Q2 | 3.48 Million PLN | 3492.78% |
| 2016 Q4 | 3.59 Million PLN | -9.87% |
| 2016 FY | 3.59 Million PLN | 175.0% |
| 2016 Q3 | 3.99 Million PLN | 14.52% |
| 2015 Q2 | -1.83 Million PLN | 60.52% |
| 2015 Q1 | -4.65 Million PLN | -10.81% |
| 2015 FY | 1.3 Million PLN | 131.14% |
| 2015 Q4 | 1.3 Million PLN | 174.96% |
| 2015 Q3 | -1.74 Million PLN | 5.06% |
| 2014 Q2 | -6.77 Million PLN | -6.55% |
| 2014 FY | -4.2 Million PLN | 62.28% |
| 2014 Q4 | -4.2 Million PLN | 12.59% |
| 2014 Q3 | -4.8 Million PLN | 29.01% |
| 2014 Q1 | -6.35 Million PLN | 42.95% |
| 2013 Q1 | 3.19 Million PLN | 201.27% |
| 2013 FY | -11.13 Million PLN | -248.36% |
| 2013 Q3 | -11.48 Million PLN | 0.0% |
| 2013 Q4 | -11.13 Million PLN | 3.02% |
| 2012 FY | -3.19 Million PLN | 0.0% |
| 2012 Q4 | -3.15 Million PLN | 0.0% |
| 2011 FY | - PLN | 0.0% |
| 2010 FY | - PLN | 100.0% |
| 2009 FY | -8.76 Million PLN | 25.19% |
| 2008 FY | -11.71 Million PLN | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioceltix S.A. | -9.13 Million PLN | -141.439% |
| BIOTON S.A. | 64.81 Million PLN | 134.032% |
| Captor Therapeutics Spolka Akcyjna | -71.92 Million PLN | 69.335% |
| Mabion S.A. | -11.98 Million PLN | -83.969% |
| Molecure S.A. | -56.84 Million PLN | 61.202% |
| NanoGroup S.A. | -537.61 Thousand PLN | -4002.587% |
| Poltreg S.A. | -57.75 Million PLN | 61.812% |
| Pure Biologics Spólka Akcyjna | 9.33 Million PLN | 336.348% |
| Ryvu Therapeutics S.A. | -57.03 Million PLN | 61.328% |
| Synthaverse S.A. | 67.86 Million PLN | 132.498% |
| Urteste S.A. | -512 Thousand PLN | -4207.813% |